Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Adaptive behavior in autism: Minimal clinically important differences on the Vineland-II.

Chatham CH, Taylor KI, Charman T, Liogier D'ardhuy X, Eule E, Fedele A, Hardan AY, Loth E, Murtagh L, Del Valle Rubido M, San Jose Caceres A, Sevigny J, Sikich L, Snyder L, Tillmann JE, Ventola PE, Walton-Bowen KL, Wang PP, Willgoss T, Bolognani F.

Autism Res. 2018 Feb;11(2):270-283. doi: 10.1002/aur.1874. Epub 2017 Sep 21.

2.

Arbaclofen in fragile X syndrome: results of phase 3 trials.

Berry-Kravis E, Hagerman R, Visootsak J, Budimirovic D, Kaufmann WE, Cherubini M, Zarevics P, Walton-Bowen K, Wang P, Bear MF, Carpenter RL.

J Neurodev Disord. 2017 Jun 12;9:3. doi: 10.1186/s11689-016-9181-6. eCollection 2017.

3.

Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial.

Veenstra-VanderWeele J, Cook EH, King BH, Zarevics P, Cherubini M, Walton-Bowen K, Bear MF, Wang PP, Carpenter RL.

Neuropsychopharmacology. 2017 Jun;42(7):1390-1398. doi: 10.1038/npp.2016.237. Epub 2016 Oct 17.

4.

STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study.

Erickson CA, Veenstra-Vanderweele JM, Melmed RD, McCracken JT, Ginsberg LD, Sikich L, Scahill L, Cherubini M, Zarevics P, Walton-Bowen K, Carpenter RL, Bear MF, Wang PP, King BH.

J Autism Dev Disord. 2014 Apr;44(4):958-64. doi: 10.1007/s10803-013-1963-z.

PMID:
24272415
5.

Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial.

Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, Mu Y, Nguyen DV, Gonzalez-Heydrich J, Wang PP, Carpenter RL, Bear MF, Hagerman RJ.

Sci Transl Med. 2012 Sep 19;4(152):152ra127.

6.

Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma.

Watkins PB, Dube LM, Walton-Bowen K, Cameron CM, Kasten LE.

Drug Saf. 2007;30(9):805-15.

PMID:
17722971
7.

Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study.

Nelson H, Kemp J, Berger W, Corren J, Casale T, Dube L, Walton-Bowen K, LaVallee N, Stepanians M.

Ann Allergy Asthma Immunol. 2007 Aug;99(2):178-84.

PMID:
17718106
8.

The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study.

Wenzel S, Busse W, Calhoun W, Panettieri R Jr, Peters-Golden M, Dube L, Walton-Bowen K, Russell H, Harris J.

J Asthma. 2007 May;44(4):305-10.

PMID:
17530530
9.

Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).

Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport DM, Berger KI, Swiedler SJ, Kakkis ED, Braakman T, Chadbourne E, Walton-Bowen K, Cox GF.

J Pediatr. 2004 May;144(5):581-8.

PMID:
15126990
10.

Safety of budesonide inhalation suspension (Pulmicort Respules) after up to 52 weeks of treatment in infants and young children with persistent asthma.

Leflein JG, Gawchik SM, Galant SP, Lyzell E, Young M, Cruz-Rivera M, Walton-Bowen K, Smith JA, Fitzpatrick S.

Allergy Asthma Proc. 2001 Nov-Dec;22(6):359-66.

PMID:
11775393
11.

Comparable efficacy of administration with face mask or mouthpiece of nebulized budesonide inhalation suspension for infants and young children with persistent asthma.

Mellon M, Leflein J, Walton-Bowen K, Cruz-Rivera M, Fitzpatrick S, Smith JA.

Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):593-8.

PMID:
10934092
12.

Longitudinal growth in infants and young children treated with budesonide inhalation suspension for persistent asthma.

Skoner DP, Szefler SJ, Welch M, Walton-Bowen K, Cruz-Rivera M, Smith JA.

J Allergy Clin Immunol. 2000 Feb;105(2 Pt 1):259-68.

PMID:
10669845
13.

Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children.

Kemp JP, Skoner DP, Szefler SJ, Walton-Bowen K, Cruz-Rivera M, Smith JA.

Ann Allergy Asthma Immunol. 1999 Sep;83(3):231-9.

PMID:
10507269
14.
15.
16.

Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma.

Shapiro G, Mendelson L, Kraemer MJ, Cruz-Rivera M, Walton-Bowen K, Smith JA.

J Allergy Clin Immunol. 1998 Nov;102(5):789-96.

PMID:
9819296
17.

Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group.

Hanauer SB, Robinson M, Pruitt R, Lazenby AJ, Persson T, Nilsson LG, Walton-Bowen K, Haskell LP, Levine JG.

Gastroenterology. 1998 Sep;115(3):525-32.

PMID:
9721148
18.

Influence of the dosing interval on prolactin release after remoxipride.

Movin-Osswald G, Hammarlund-Udenaes M, Von Bahr C, Eneroth P, Walton-Bowen K.

Br J Clin Pharmacol. 1995 May;39(5):503-10.

19.

Monitoring of clinical trials and interim analyses from a drug sponsor's point of view.

Williams GW, Davis RL, Getson AJ, Gould AL, Hwang IK, Matthews H, Shih WJ, Snapinn SM, Walton-Bowen KL.

Stat Med. 1993 Mar;12(5-6):481-92. Review.

PMID:
8493426

Supplemental Content

Loading ...
Support Center